{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:44:22Z","timestamp":1793335462408,"version":"4.5.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AI157817"],"award-info":[{"award-number":["R21 AI157817"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32MH080634"],"award-info":[{"award-number":["T32MH080634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40265-021-01530-0","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T10:04:49Z","timestamp":1623060289000},"page":"1153-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2800-9501","authenticated-orcid":false,"given":"Eric Y","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-6458","authenticated-orcid":false,"given":"Paul C","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-7364","authenticated-orcid":false,"given":"Jeffrey D.","family":"Klausner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"1","key":"1530_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"M Unemo","year":"2019","unstructured":"Unemo M, Seifert HS, Hook EW 3rd, Hawkes S, Ndowa F, Dillon JR. Gonorrhoea. Nat Rev Dis Primers. 2019;5(1):79. https:\/\/doi.org\/10.1038\/s41572-019-0128-6.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1530_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jamainternmed.2018.4345","volume":"179","author":"N Keshvani","year":"2019","unstructured":"Keshvani N, Gupta A, Incze MA. I am worried about gonorrhea: what do i need to know? JAMA Intern Med. 2019;179(1):132. https:\/\/doi.org\/10.1001\/jamainternmed.2018.4345.","journal-title":"JAMA Intern Med"},{"key":"1530_CR3","unstructured":"World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: World Health Organization; 2012. https:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/9789241503501\/en\/."},{"key":"1530_CR4","volume-title":"Report on global sexually transmitted infection surveillance, 2018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Report on global sexually transmitted infection surveillance, 2018. Geneva: Switzerland; 2018."},{"issue":"8","key":"1530_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2471\/blt.18.228486","volume":"97","author":"J Rowley","year":"2019","unstructured":"Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548\u201362. https:\/\/doi.org\/10.2471\/blt.18.228486.","journal-title":"Bull World Health Organ"},{"issue":"12","key":"1530_CR6","doi-asserted-by":"publisher","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","volume":"10","author":"L Newman","year":"2015","unstructured":"Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE. 2015;10(12):e0143304. https:\/\/doi.org\/10.1371\/journal.pone.0143304.","journal-title":"PLoS ONE"},{"issue":"7","key":"1530_CR7","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1128\/aac.00325-11","volume":"55","author":"M Ohnishi","year":"2011","unstructured":"Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538\u201345. https:\/\/doi.org\/10.1128\/aac.00325-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1530_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/s1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327. https:\/\/doi.org\/10.1016\/s1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"key":"1530_CR9","unstructured":"World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. Geneva: World Health Organization; 2016. https:\/\/apps.who.int\/iris\/handle\/10665\/246114."},{"issue":"1","key":"1530_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0956462419886775","volume":"31","author":"H Fifer","year":"2020","unstructured":"Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS. 2020;31(1):4\u201315. https:\/\/doi.org\/10.1177\/0956462419886775.","journal-title":"Int J STD AIDS"},{"key":"1530_CR11","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2019.24.8.1900118","author":"AV Jennison","year":"2019","unstructured":"Jennison AV, Whiley D, Lahra MM, Graham RM, Cole MJ, Hughes G, et al. Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018. Euro Surveill. 2019. https:\/\/doi.org\/10.2807\/1560-7917.Es.2019.24.8.1900118.","journal-title":"Euro Surveill"},{"key":"1530_CR12","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2019.24.10.1900147","author":"DW Eyre","year":"2019","unstructured":"Eyre DW, Town K, Street T, Barker L, Sanderson N, Cole MJ, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro Surveill. 2019. https:\/\/doi.org\/10.2807\/1560-7917.Es.2019.24.10.1900147.","journal-title":"Euro Surveill"},{"issue":"1","key":"1530_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12864-020-6511-6","volume":"21","author":"D Golparian","year":"2020","unstructured":"Golparian D, Harris SR, S\u00e1nchez-Bus\u00f3 L, Hoffmann S, Shafer WM, Bentley SD, et al. Genomic evolution of Neisseria gonorrhoeae since the preantibiotic era (1928\u20132013): antimicrobial use\/misuse selects for resistance and drives evolution. BMC Genom. 2020;21(1):116. https:\/\/doi.org\/10.1186\/s12864-020-6511-6.","journal-title":"BMC Genom"},{"issue":"11","key":"1530_CR14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41564-019-0501-y","volume":"4","author":"L S\u00e1nchez-Bus\u00f3","year":"2019","unstructured":"S\u00e1nchez-Bus\u00f3 L, Golparian D, Corander J, Grad YH, Ohnishi M, Flemming R, et al. The impact of antimicrobials on gonococcal evolution. Nat Microbiol. 2019;4(11):1941\u201350. https:\/\/doi.org\/10.1038\/s41564-019-0501-y.","journal-title":"Nat Microbiol"},{"issue":"3","key":"1530_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/cmr.00010-14","volume":"27","author":"M Unemo","year":"2014","unstructured":"Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587\u2013613. https:\/\/doi.org\/10.1128\/cmr.00010-14.","journal-title":"Clin Microbiol Rev"},{"key":"1530_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics7020049","author":"B Suay-Garc\u00eda","year":"2018","unstructured":"Suay-Garc\u00eda B, P\u00e9rez-Gracia MT. Future prospects for Neisseria gonorrhoeae treatment. Antibiotics (Basel). 2018. https:\/\/doi.org\/10.3390\/antibiotics7020049.","journal-title":"Antibiotics (Basel)."},{"key":"1530_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.EI10-0009-2015","author":"M Unemo","year":"2016","unstructured":"Unemo M, Del Rio C, Shafer WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr. 2016. https:\/\/doi.org\/10.1128\/microbiolspec.EI10-0009-2015.","journal-title":"Microbiol Spectr."},{"key":"1530_CR18","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1111\/j.1749-6632.2011.06215.x","volume":"1230","author":"M Unemo","year":"2011","unstructured":"Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci. 2011;1230:E19-28. https:\/\/doi.org\/10.1111\/j.1749-6632.2011.06215.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"13","key":"1530_CR19","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.3201\/eid2313.170443","volume":"23","author":"EJ Weston","year":"2017","unstructured":"Weston EJ, Wi T, Papp J. Strengthening global surveillance for antimicrobial drug-resistant Neisseria gonorrhoeae through the enhanced gonococcal antimicrobial surveillance program. Emerg Infect Dis. 2017;23(13):S47-52. https:\/\/doi.org\/10.3201\/eid2313.170443.","journal-title":"Emerg Infect Dis"},{"key":"1530_CR20","volume-title":"Report of the Enhanced Surveillance of Antimicrobial-Resistance Gonorrhea (ESAG)","author":"Public Health Agency of Canada","year":"2019","unstructured":"Public Health Agency of Canada. Report of the Enhanced Surveillance of Antimicrobial-Resistance Gonorrhea (ESAG). Ottawa: Public Health Agency of Canada; 2019."},{"issue":"8","key":"1530_CR21","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/s1473-3099(20)30171-7","volume":"20","author":"AC Se\u00f1a","year":"2020","unstructured":"Se\u00f1a AC, Bachmann L, Johnston C, Wi T, Workowski K, Hook EW 3rd, et al. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infect Dis. 2020;20(8):e181\u201391. https:\/\/doi.org\/10.1016\/s1473-3099(20)30171-7.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"1530_CR22","doi-asserted-by":"publisher","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","volume":"14","author":"T Wi","year":"2017","unstructured":"Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 2017;14(7):e1002344. https:\/\/doi.org\/10.1371\/journal.pmed.1002344.","journal-title":"PLoS Med"},{"issue":"1","key":"1530_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12879-018-3528-4","volume":"18","author":"MJ Day","year":"2018","unstructured":"Day MJ, Spiteri G, Jacobsson S, Woodford N, Amato-Gauci AJ, Cole MJ, et al. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. BMC Infect Dis. 2018;18(1):609. https:\/\/doi.org\/10.1186\/s12879-018-3528-4.","journal-title":"BMC Infect Dis"},{"key":"1530_CR24","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018: Gonococcal Isolate Surveillance Project (GISP) Supplement and Profiles. Atlanta: U.S. Department of Health and Human Services; 2020."},{"key":"1530_CR25","first-page":"2019","volume-title":"Report on the enhanced surveillance of antimicrobial-resistant gonorrhea (ESAG)\u2014results from 2014 and 2015","author":"Public Health Agency of Canada","year":"2019","unstructured":"Public Health Agency of Canada. Report on the enhanced surveillance of antimicrobial-resistant gonorrhea (ESAG)\u2014results from 2014 and 2015. Ottawa: Public Health Agency of Canada; 2019. p. 2019."},{"key":"1530_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.33321\/cdi.2019.43.19","volume":"2019","author":"MM Lahra","year":"2018","unstructured":"Lahra MM, Enriquez RP, George CRR. Australian Gonococcal Surveillance Programme, 1 July to 30 September 2018. Commun Dis Intell. 2018;2019:43. https:\/\/doi.org\/10.33321\/cdi.2019.43.19.","journal-title":"Commun Dis Intell"},{"key":"1530_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.33321\/cdi.2020.44.37","volume":"2020","author":"MM Lahra","year":"2018","unstructured":"Lahra MM, Hogan TR. Australian Gonococcal Surveillance Programme, 1 April to 30 June 2019. Commun Dis Intell. 2018;2020:44. https:\/\/doi.org\/10.33321\/cdi.2020.44.37.","journal-title":"Commun Dis Intell"},{"issue":"4","key":"1530_CR28","doi-asserted-by":"publisher","first-page":"e0213312","DOI":"10.1371\/journal.pone.0213312","volume":"14","author":"CRR George","year":"2019","unstructured":"George CRR, Enriquez RP, Gatus BJ, Whiley DM, Lo YR, Ishikawa N, et al. Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016. PLoS ONE. 2019;14(4):e0213312. https:\/\/doi.org\/10.1371\/journal.pone.0213312.","journal-title":"PLoS ONE"},{"issue":"2","key":"1530_CR29","doi-asserted-by":"publisher","first-page":"e1002499","DOI":"10.1371\/journal.pmed.1002499","volume":"15","author":"YP Yin","year":"2018","unstructured":"Yin YP, Han Y, Dai XQ, Zheng HP, Chen SC, Zhu BY, et al. Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: a retrospective study of national surveillance data from 2013 to 2016. PLoS Med. 2018;15(2):e1002499. https:\/\/doi.org\/10.1371\/journal.pmed.1002499.","journal-title":"PLoS Med"},{"issue":"7","key":"1530_CR30","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/jac\/dky090","volume":"73","author":"ML Bazzo","year":"2018","unstructured":"Bazzo ML, Golfetto L, Gaspar PC, Pires AF, Ramos MC, Franchini M, et al. First nationwide antimicrobial susceptibility surveillance for Neisseria gonorrhoeae in Brazil, 2015\u201316. J Antimicrob Chemother. 2018;73(7):1854\u201361. https:\/\/doi.org\/10.1093\/jac\/dky090.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1530_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.17843\/rpmesp.2018.351.3552","volume":"35","author":"A Jorge-Berrocal","year":"2018","unstructured":"Jorge-Berrocal A, Mayta-Barrios M, Fiestas-Sol\u00f3rzano V. Antimicrobial resistance of Neisseria gonorrhoeae in Peru. Rev Peru Med Exp Salud Publica. 2018;35(1):155\u20136. https:\/\/doi.org\/10.17843\/rpmesp.2018.351.3552.","journal-title":"Rev Peru Med Exp Salud Publica"},{"issue":"1","key":"1530_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1186\/s12879-017-2713-1","volume":"17","author":"BT Tadesse","year":"2017","unstructured":"Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, Gonz\u00e1lez IJ, et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17(1):616. https:\/\/doi.org\/10.1186\/s12879-017-2713-1.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1530_CR33","doi-asserted-by":"publisher","first-page":"e17009","DOI":"10.2196\/17009","volume":"6","author":"M Workneh","year":"2020","unstructured":"Workneh M, Hamill MM, Kakooza F, Mande E, Wagner J, Mbabazi O, et al. Antimicrobial resistance of Neisseria Gonorrhoeae in a newly implemented surveillance program in Uganda: surveillance report. JMIR Public Health Surveill. 2020;6(2):e17009. https:\/\/doi.org\/10.2196\/17009.","journal-title":"JMIR Public Health Surveill"},{"key":"1530_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics7030058","author":"R Kularatne","year":"2018","unstructured":"Kularatne R, Maseko V, Gumede L, Kufa T. Trends in Neisseria gonorrhoeae antimicrobial resistance over a ten-year surveillance period, Johannesburg, South Africa, 2008\u20132017. Antibiotics (Basel). 2018. https:\/\/doi.org\/10.3390\/antibiotics7030058.","journal-title":"Antibiotics (Basel)."},{"key":"1530_CR35","doi-asserted-by":"publisher","first-page":"7672024","DOI":"10.1155\/2020\/7672024","volume":"2020","author":"A Sahile","year":"2020","unstructured":"Sahile A, Teshager L, Fekadie M, Gashaw M. Prevalence and antimicrobial susceptibility patterns of Neisseria gonorrhoeae among suspected patients attending private clinics in Jimma. Ethiopia Int J Microbiol. 2020;2020:7672024. https:\/\/doi.org\/10.1155\/2020\/7672024.","journal-title":"Ethiopia. Int J Microbiol."},{"issue":"6","key":"1530_CR36","doi-asserted-by":"publisher","first-page":"e0233753","DOI":"10.1371\/journal.pone.0233753","volume":"15","author":"S Fentaw","year":"2020","unstructured":"Fentaw S, Abubeker R, Asamene N, Assefa M, Bekele Y, Tigabu E. Antimicrobial susceptibility profile of Gonococcal isolates obtained from men presenting with urethral discharge in Addis Ababa, Ethiopia: implications for national syndromic treatment guideline. PLoS ONE. 2020;15(6):e0233753. https:\/\/doi.org\/10.1371\/journal.pone.0233753.","journal-title":"PLoS ONE"},{"issue":"3","key":"1530_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/aac.05760-11","volume":"56","author":"M Unemo","year":"2012","unstructured":"Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273\u201380. https:\/\/doi.org\/10.1128\/aac.05760-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"1530_CR38","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1056\/NEJMc1408109","volume":"371","author":"MM Lahra","year":"2014","unstructured":"Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med. 2014;371(19):1850\u20131. https:\/\/doi.org\/10.1056\/NEJMc1408109.","journal-title":"N Engl J Med"},{"issue":"1","key":"1530_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3201\/eid2201.150868","volume":"22","author":"T Deguchi","year":"2016","unstructured":"Deguchi T, Yasuda M, Hatazaki K, Kameyama K, Horie K, Kato T, et al. New clinical strain of Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone, Japan. Emerg Infect Dis. 2016;22(1):142\u20134. https:\/\/doi.org\/10.3201\/eid2201.150868.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"1530_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3201\/eid2404.171873","volume":"24","author":"MM Lahra","year":"2018","unstructured":"Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis. 2018;24(4):735\u201340. https:\/\/doi.org\/10.3201\/eid2404.171873.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"1530_CR41","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3201\/eid2509.190407","volume":"25","author":"BM Berenger","year":"2019","unstructured":"Berenger BM, Demczuk W, Gratrix J, Pabbaraju K, Smyczek P, Martin I. Genetic characterization and enhanced surveillance of ceftriaxone-resistant Neisseria gonorrhoeae strain, Alberta, Canada, 2018. Emerg Infect Dis. 2019;25(9):1660\u20137. https:\/\/doi.org\/10.3201\/eid2509.190407.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"1530_CR42","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3201\/eid2507.190172","volume":"25","author":"SC Chen","year":"2019","unstructured":"Chen SC, Han Y, Yuan LF, Zhu XY, Yin YP. Identification of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain FC428, China. Emerg Infect Dis. 2019;25(7):1427\u20139. https:\/\/doi.org\/10.3201\/eid2507.190172.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"1530_CR43","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1093\/jac\/dkz384","volume":"74","author":"F Yang","year":"2019","unstructured":"Yang F, Zhang H, Chen Y, Zhai Y, Zhao F, Yu Y, et al. Detection and analysis of two cases of the internationally spreading ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in China. J Antimicrob Chemother. 2019;74(12):3635\u20136. https:\/\/doi.org\/10.1093\/jac\/dkz384.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"1530_CR44","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1093\/jac\/dkaa123","volume":"75","author":"H Wang","year":"2020","unstructured":"Wang H, Wang Y, Yong G, Li X, Yu L, Ma S, et al. Emergence and genomic characterization of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in Chengdu, China. J Antimicrob Chemother. 2020;75(9):2495\u20138. https:\/\/doi.org\/10.1093\/jac\/dkaa123.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"1530_CR45","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/jac\/dkaa196","volume":"75","author":"SC Chen","year":"2020","unstructured":"Chen SC, Yuan LF, Zhu XY, van der Veen S, Yin YP. Sustained transmission of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in China. J Antimicrob Chemother. 2020;75(9):2499\u2013502. https:\/\/doi.org\/10.1093\/jac\/dkaa196.","journal-title":"J Antimicrob Chemother"},{"key":"1530_CR46","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2018.23.47.1800617","author":"D Golparian","year":"2018","unstructured":"Golparian D, Rose L, Lynam A, Mohamed A, Bercot B, Ohnishi M, et al. Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. Euro Surveill. 2018. https:\/\/doi.org\/10.2807\/1560-7917.Es.2018.23.47.1800617.","journal-title":"Euro Surveill"},{"key":"1530_CR47","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2019.24.36.1900528","author":"T Poncin","year":"2019","unstructured":"Poncin T, Merimeche M, Braille A, Mainardis M, Bebear C, Jacquier H, et al. Two cases of multidrug-resistant Neisseria gonorrhoeae related to travel in south-eastern Asia, France, June 2019. Euro Surveill. 2019. https:\/\/doi.org\/10.2807\/1560-7917.Es.2019.24.36.1900528.","journal-title":"Euro Surveill"},{"issue":"1","key":"1530_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"M Unemo","year":"2019","unstructured":"Unemo M, Seifert HS, Hook EW, Hawkes S, Ndowa F, Dillon J-AR. Gonorrhoea. Nat Rev Dis Primers. 2019;5(1):79. https:\/\/doi.org\/10.1038\/s41572-019-0128-6.","journal-title":"Nat Rev Dis Primers"},{"key":"1530_CR49","doi-asserted-by":"publisher","unstructured":"St. Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR Morbidity Mortality Weekly Report. 2020;69(50):1911\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm6950a6.","DOI":"10.15585\/mmwr.mm6950a6"},{"key":"1530_CR50","doi-asserted-by":"publisher","unstructured":"Wang Q-Q, Zhang R-L, Liu Q-Z, Xu J-H, Su X-H, Yin Y-P, et al. National guidelines on diagnosis and treatment of gonorrhea in China. Int J Dermatol Venereol. 2020;3(3):129\u201334. https:\/\/doi.org\/10.1097\/JD9.0000000000000072.","DOI":"10.1097\/JD9.0000000000000072"},{"issue":"1","key":"1530_CR51","first-page":"23","volume":"67","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T. Guidelines on the diagnosis and treatment of sexually transmitted diseases. Nihon Rinsho. 2009;67(1):23\u20139.","journal-title":"Nihon Rinsho"},{"issue":"25","key":"1530_CR52","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1512757","volume":"374","author":"H Fifer","year":"2016","unstructured":"Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med. 2016;374(25):2504\u20136. https:\/\/doi.org\/10.1056\/NEJMc1512757.","journal-title":"N Engl J Med"},{"key":"1530_CR53","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.es.2018.23.27.1800323","author":"DW Eyre","year":"2018","unstructured":"Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance. 2018. https:\/\/doi.org\/10.2807\/1560-7917.es.2018.23.27.1800323.","journal-title":"Eurosurveillance"},{"issue":"3","key":"1530_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrurol.2016.268","volume":"14","author":"M Unemo","year":"2017","unstructured":"Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017;14(3):139\u201352. https:\/\/doi.org\/10.1038\/nrurol.2016.268.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"1530_CR55","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1071\/sh19023","volume":"16","author":"M Unemo","year":"2019","unstructured":"Unemo M, Lahra MM, Cole M, Galarza P, Ndowa F, Martin I, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health. 2019;16(5):412\u201325. https:\/\/doi.org\/10.1071\/sh19023.","journal-title":"Sex Health"},{"key":"1530_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa495","author":"EY Lin","year":"2020","unstructured":"Lin EY, Adamson PC, Deng X, Klausner JD. Establishing novel molecular algorithms to predict decreased susceptibility to ceftriaxone in Neisseria gonorrhoeae strains. J Infect Dis. 2020. https:\/\/doi.org\/10.1093\/infdis\/jiaa495.","journal-title":"J Infect Dis"},{"key":"1530_CR57","doi-asserted-by":"crossref","unstructured":"Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea. In: Christodoulides M, editor. Neisseria gonorrhoeae: methods and protocols. New York: Springer New York; 2019. p. 37\u201358.","DOI":"10.1007\/978-1-4939-9496-0_3"},{"issue":"4","key":"1530_CR58","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1128\/jcm.01909-06","volume":"45","author":"MJ Siedner","year":"2007","unstructured":"Siedner MJ, Pandori M, Castro L, Barry P, Whittington WL, Liska S, et al. Real-time PCR assay for detection of quinolone-resistant Neisseria gonorrhoeae in urine samples. J Clin Microbiol. 2007;45(4):1250\u20134. https:\/\/doi.org\/10.1128\/jcm.01909-06.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"1530_CR59","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1128\/jcm.03032-15","volume":"54","author":"P Hemarajata","year":"2016","unstructured":"Hemarajata P, Yang S, Soge OO, Humphries RM, Klausner JD. Performance and verification of a real-time PCR assay targeting the gyrA gene for prediction of ciprofloxacin resistance in Neisseria gonorrhoeae. J Clin Microbiol. 2016;54(3):805\u20138. https:\/\/doi.org\/10.1128\/jcm.03032-15.","journal-title":"J Clin Microbiol"},{"key":"1530_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa596","author":"JD Klausner","year":"2020","unstructured":"Klausner JD, Bristow CC, Soge OO, Shahkolahi A, Waymer T, Bolan RK, et al. Resistance-guided treatment of gonorrhea: a prospective clinical study. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa596.","journal-title":"Clin Infect Dis"},{"key":"1530_CR61","doi-asserted-by":"publisher","unstructured":"Chaudry AE, Klausner JD. A Narrative review of clinical treatment outcomes of Neisseria gonorrhoeae infection with ciprofloxacin by minimum inhibitory concentration and anatomic site. Sex Transm Dis.\u00a02021;48(6):385\u201392. https:\/\/doi.org\/10.1097\/olq.0000000000001334.","DOI":"10.1097\/olq.0000000000001334"},{"key":"1530_CR62","doi-asserted-by":"publisher","DOI":"10.1071\/SH18227","author":"X Deng","year":"2019","unstructured":"Deng X, Allan-Blitz L-T, Klausner JD. Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility. Sex Health. 2019. https:\/\/doi.org\/10.1071\/SH18227.","journal-title":"Sex Health"},{"issue":"5","key":"1530_CR63","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/infdis\/jiz504","volume":"221","author":"X Deng","year":"2019","unstructured":"Deng X, Klausner JD. Six penA codons accurately and reliably predict cefixime-decreased susceptibility in Neisseria gonorrhoeae. J Infect Dis. 2019;221(5):851\u20132. https:\/\/doi.org\/10.1093\/infdis\/jiz504.","journal-title":"J Infect Dis"},{"issue":"7","key":"1530_CR64","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa041681","volume":"352","author":"MR Golden","year":"2005","unstructured":"Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005;352(7):676\u201385. https:\/\/doi.org\/10.1056\/NEJMoa041681.","journal-title":"N Engl J Med"},{"issue":"1","key":"1530_CR65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/cid\/ciz170","volume":"70","author":"Y Han","year":"2020","unstructured":"Han Y, Yin Y, Dai X, Chen S, Yang L, Zhu B, et al. Widespread use of high-dose ceftriaxone therapy for uncomplicated gonorrhea without reported ceftriaxone treatment failure: results from 5 years of multicenter surveillance data in China. Clin Infect Dis. 2020;70(1):99\u2013105. https:\/\/doi.org\/10.1093\/cid\/ciz170.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1530_CR66","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/jcm.00493-15","volume":"53","author":"SW Peterson","year":"2015","unstructured":"Peterson SW, Martin I, Demczuk W, Bharat A, Hoang L, Wylie J, et al. Molecular assay for detection of genetic markers associated with decreased susceptibility to cephalosporins in Neisseria gonorrhoeae. J Clin Microbiol. 2015;53(7):2042\u20138. https:\/\/doi.org\/10.1128\/jcm.00493-15.","journal-title":"J Clin Microbiol"},{"key":"1530_CR67","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00365-18","author":"V Don\u00e0","year":"2018","unstructured":"Don\u00e0 V, Smid JH, Kasraian S, Egli-Gany D, Dost F, Imeri F, et al. Mismatch amplification mutation assay-based real-time PCR for rapid detection of Neisseria gonorrhoeae and antimicrobial resistance determinants in clinical specimens. J Clin Microbiol. 2018. https:\/\/doi.org\/10.1128\/jcm.00365-18.","journal-title":"J Clin Microbiol"},{"issue":"12","key":"1530_CR68","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1093\/jac\/dkaa360","volume":"75","author":"SW Peterson","year":"2020","unstructured":"Peterson SW, Martin I, Demczuk W, Barairo N, Naidu P, Lefebvre B, et al. Multiplex real-time PCR assays for the prediction of cephalosporin, ciprofloxacin and azithromycin antimicrobial susceptibility of positive Neisseria gonorrhoeae nucleic acid amplification test samples. J Antimicrob Chemother. 2020;75(12):3485\u201390. https:\/\/doi.org\/10.1093\/jac\/dkaa360.","journal-title":"J Antimicrob Chemother"},{"key":"1530_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa525","author":"EY Lin","year":"2020","unstructured":"Lin EY, Adamson PC, Klausner JD. Evaluating the generalizability of a multiplex real-time PCR assay for predicting decreased susceptibility to ceftriaxone in a global set of Neisseria gonorrhoeae sequences. J Antimicrob Chemother. 2020. https:\/\/doi.org\/10.1093\/jac\/dkaa525.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1530_CR70","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/olq.0000000000001274","volume":"47","author":"EY Lin","year":"2020","unstructured":"Lin EY, Adamson PC, Klausner JD. Molecular algorithms accurately predict decreased susceptibility to ceftriaxone in Neisseria gonorrhoeae. Sex Transm Dis. 2020;47(12):e63\u20134. https:\/\/doi.org\/10.1097\/olq.0000000000001274.","journal-title":"Sex Transm Dis"},{"issue":"1","key":"1530_CR71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/apm.12777","volume":"126","author":"A J\u00f6nsson","year":"2018","unstructured":"J\u00f6nsson A, Foerster S, Golparian D, Hamasuna R, Jacobsson S, Lindberg M, et al. In vitro activity and time-kill curve analysis of sitafloxacin against a global panel of antimicrobial-resistant and multidrug-resistant Neisseria gonorrhoeae isolates. APMIS. 2018;126(1):29\u201337. https:\/\/doi.org\/10.1111\/apm.12777.","journal-title":"APMIS"},{"issue":"1","key":"1530_CR72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1089\/mdr.2017.0054","volume":"24","author":"R Hamasuna","year":"2018","unstructured":"Hamasuna R, Ohnishi M, Matsumoto M, Okumura R, Unemo M, Matsumoto T. In vitro activity of sitafloxacin and additional newer generation fluoroquinolones against ciprofloxacin-resistant Neisseria gonorrhoeae isolates. Microb Drug Resist. 2018;24(1):30\u20134. https:\/\/doi.org\/10.1089\/mdr.2017.0054.","journal-title":"Microb Drug Resist"},{"issue":"7","key":"1530_CR73","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/jac\/dkaa108","volume":"75","author":"LA Barbee","year":"2020","unstructured":"Barbee LA, Golden MR. Aztreonam for Neisseria gonorrhoeae: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(7):1685\u20138. https:\/\/doi.org\/10.1093\/jac\/dkaa108.","journal-title":"J Antimicrob Chemother"},{"key":"1530_CR74","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01739-20","author":"LA Barbee","year":"2020","unstructured":"Barbee LA, Soge OO, Ocbamichael N, LeClair A, Golden MR. A single-arm open-label clinical trial of 2g aztreonam for the treatment of N. gonorrhoeae. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/aac.01739-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1530_CR75","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cmi.2019.08.004","volume":"26","author":"F Rob","year":"2020","unstructured":"Rob F, Klubalov\u00e1 B, Ny\u010dov\u00e1 E, Hercogov\u00e1 J, Unemo M. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clin Microbiol Infect. 2020;26(2):207\u201312. https:\/\/doi.org\/10.1016\/j.cmi.2019.08.004.","journal-title":"Clin Microbiol Infect"},{"issue":"10190","key":"1530_CR76","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/s0140-6736(18)32817-4","volume":"393","author":"JDC Ross","year":"2019","unstructured":"Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet. 2019;393(10190):2511\u201320. https:\/\/doi.org\/10.1016\/s0140-6736(18)32817-4.","journal-title":"Lancet"},{"issue":"7","key":"1530_CR77","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1099\/jmm.0.001014","volume":"68","author":"F Fuchs","year":"2019","unstructured":"Fuchs F, Wille J, Hamprecht A, Parcina M, Lehmann C, Schwarze-Zander C, et al. In vitro activity of mecillinam and nitroxoline against Neisseria gonorrhoeae\u2014re-purposing old antibiotics in the multi-drug resistance era. J Med Microbiol. 2019;68(7):991\u20135. https:\/\/doi.org\/10.1099\/jmm.0.001014.","journal-title":"J Med Microbiol"},{"key":"1530_CR78","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01225-19","author":"M Alhashimi","year":"2019","unstructured":"Alhashimi M, Mayhoub A, Seleem MN. Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.01225-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1530_CR79","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02377-17","author":"A Cern","year":"2018","unstructured":"Cern A, Connolly KL, Jerse AE, Barenholz Y. In vitro susceptibility of Neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.02377-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1530_CR80","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02206-19","author":"YJ Seong","year":"2020","unstructured":"Seong YJ, Alhashimi M, Mayhoub A, Mohammad H, Seleem MN. Repurposing fenamic acid drugs to combat multidrug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/aac.02206-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1530_CR81","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/jac\/dkz012","volume":"74","author":"S Riedel","year":"2019","unstructured":"Riedel S, Vijayakumar D, Berg G, Kang AD, Smith KP, Kirby JE. Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae. J Antimicrob Chemother. 2019;74(5):1311\u20136. https:\/\/doi.org\/10.1093\/jac\/dkz012.","journal-title":"J Antimicrob Chemother"},{"key":"1530_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/jam.14858","author":"NL Heath","year":"2020","unstructured":"Heath NL, Rowlands RS, Webster G, Mahenthiralingam E, Beeton ML. Antimicrobial activity of enacyloxin IIa and gladiolin against the urogenital pathogens Neisseria gonorrhoeae and Ureaplasma spp. J Appl Microbiol. 2020. https:\/\/doi.org\/10.1111\/jam.14858.","journal-title":"J Appl Microbiol"},{"issue":"3","key":"1530_CR83","doi-asserted-by":"publisher","first-page":"e0193678","DOI":"10.1371\/journal.pone.0193678","volume":"13","author":"V Singh","year":"2018","unstructured":"Singh V, Bala M, Bhargava A, Kakran M, Bhatnagar R. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. PLoS ONE. 2018;13(3):e0193678. https:\/\/doi.org\/10.1371\/journal.pone.0193678.","journal-title":"PLoS ONE"},{"issue":"1","key":"1530_CR84","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1038\/s41598-020-62696-3","volume":"10","author":"A Elkashif","year":"2020","unstructured":"Elkashif A, Seleem MN. Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae. Sci Rep. 2020;10(1):5602. https:\/\/doi.org\/10.1038\/s41598-020-62696-3.","journal-title":"Sci Rep"},{"key":"1530_CR85","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03046-19","author":"J Poole","year":"2020","unstructured":"Poole J, Day CJ, Haselhorst T, Jen FE, Torres VJ, Edwards JL, et al. Repurposed drugs that block the gonococcus-complement receptor 3 interaction can prevent and cure gonococcal infection of primary human cervical epithelial cells. MBio. 2020. https:\/\/doi.org\/10.1128\/mBio.03046-19.","journal-title":"MBio"},{"key":"1530_CR86","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1038\/srep11827","volume":"5","author":"GS Basarab","year":"2015","unstructured":"Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep. 2015;5:11827. https:\/\/doi.org\/10.1038\/srep11827.","journal-title":"Sci Rep"},{"issue":"1","key":"1530_CR87","doi-asserted-by":"publisher","first-page":"e01808","DOI":"10.1128\/aac.01808-18","volume":"63","author":"J O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell J, Lawrence K, Vishwanathan K, Hosagrahara V, Mueller JP. Single-dose pharmacokinetics, excretion, and metabolism of zoliflodacin, a novel spiropyrimidinetrione antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 2019;63(1):e01808-e1818. https:\/\/doi.org\/10.1128\/aac.01808-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1530_CR88","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/aac.04124-14","volume":"59","author":"MD Huband","year":"2015","unstructured":"Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015;59(1):467\u201374. https:\/\/doi.org\/10.1128\/aac.04124-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"34","key":"1530_CR89","doi-asserted-by":"publisher","first-page":"20984","DOI":"10.1074\/jbc.M115.663534","volume":"290","author":"G Kern","year":"2015","unstructured":"Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, et al. Inhibition of Neisseria gonorrhoeae Type II topoisomerases by the novel spiropyrimidinetrione AZD0914. J Biol Chem. 2015;290(34):20984\u201394. https:\/\/doi.org\/10.1074\/jbc.M115.663534.","journal-title":"J Biol Chem"},{"issue":"3","key":"1530_CR90","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.05.018","volume":"48","author":"JR Papp","year":"2016","unstructured":"Papp JR, Lawrence K, Sharpe S, Mueller J, Kirkcaldy RD. In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione. Int J Antimicrob Agents. 2016;48(3):328\u201330. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.05.018.","journal-title":"Int J Antimicrob Agents"},{"key":"1530_CR91","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01479-19","author":"S Jacobsson","year":"2019","unstructured":"Jacobsson S, Kularatne R, Kittiyaowamarn R, Maseko V, Paopang P, Sangprasert P, et al. High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015\u20132017). Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.01479-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1530_CR92","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1128\/aac.00786-15","volume":"59","author":"M Unemo","year":"2015","unstructured":"Unemo M, Ringlander J, Wiggins C, Fredlund H, Jacobsson S, Cole M. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother. 2015;59(9):5220\u20135. https:\/\/doi.org\/10.1128\/aac.00786-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1530_CR93","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1128\/aac.04456-14","volume":"59","author":"RA Alm","year":"2015","unstructured":"Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, et al. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2015;59(3):1478\u201386. https:\/\/doi.org\/10.1128\/aac.04456-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"1530_CR94","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3389\/fmicb.2015.01377","volume":"6","author":"S Foerster","year":"2015","unstructured":"Foerster S, Golparian D, Jacobsson S, Hathaway LJ, Low N, Shafer WM, et al. Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Front Microbiol. 2015;6:1377. https:\/\/doi.org\/10.3389\/fmicb.2015.01377.","journal-title":"Front Microbiol"},{"issue":"12","key":"1530_CR95","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1093\/jac\/dkz376","volume":"74","author":"S Foerster","year":"2019","unstructured":"Foerster S, Drusano G, Golparian D, Neely M, Piddock LJV, Alirol E, et al. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae. J Antimicrob Chemother. 2019;74(12):3521\u20139. https:\/\/doi.org\/10.1093\/jac\/dkz376.","journal-title":"J Antimicrob Chemother"},{"issue":"19","key":"1530_CR96","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","volume":"379","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Marrazzo J, Batteiger BE, Hook EW, Se\u00f1a AC, Long J, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379(19):1835\u201345. https:\/\/doi.org\/10.1056\/NEJMoa1706988.","journal-title":"N Engl J Med"},{"key":"1530_CR97","unstructured":"Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03959527. Accessed 15 Jan 2021."},{"issue":"5","key":"1530_CR98","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1128\/aac.00036-12","volume":"56","author":"D Golparian","year":"2012","unstructured":"Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother. 2012;56(5):2739\u201342. https:\/\/doi.org\/10.1128\/aac.00036-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1530_CR99","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/cid\/civ478","volume":"61","author":"EW Hook III","year":"2015","unstructured":"Hook EW III, Golden M, Jamieson BD, Dixon PB, Harbison HS, Lowens S, et al. A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea. Clin Infect Dis. 2015;61(7):1043\u20138. https:\/\/doi.org\/10.1093\/cid\/civ478.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1530_CR100","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/s1473-3099(19)30116-1","volume":"19","author":"MY Chen","year":"2019","unstructured":"Chen MY, McNulty A, Avery A, Whiley D, Tabrizi SN, Hardy D, et al. Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial. Lancet Infect Dis. 2019;19(8):833\u201342. https:\/\/doi.org\/10.1016\/s1473-3099(19)30116-1.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"1530_CR101","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/s1473-3099(19)30430-x","volume":"19","author":"P Fernandes","year":"2019","unstructured":"Fernandes P, Craft JC. Phase 3 trial of treating gonorrhoea with solithromycin. Lancet Infect Dis. 2019;19(9):928. https:\/\/doi.org\/10.1016\/s1473-3099(19)30430-x.","journal-title":"Lancet Infect Dis"},{"key":"1530_CR102","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02047-16","author":"DJ Farrell","year":"2017","unstructured":"Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.02047-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1530_CR103","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/jac\/dky162","volume":"73","author":"S Jacobsson","year":"2018","unstructured":"Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2018;73(8):2072\u20137. https:\/\/doi.org\/10.1093\/jac\/dky162.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1530_CR104","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cid\/ciy145","volume":"67","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67(4):504\u201312. https:\/\/doi.org\/10.1093\/cid\/ciy145.","journal-title":"Clin Infect Dis"},{"key":"1530_CR105","unstructured":"Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04010539. Accessed 15 Jan 2021."},{"issue":"6","key":"1530_CR106","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/jac\/dkz060","volume":"74","author":"S Jacobsson","year":"2019","unstructured":"Jacobsson S, Mason C, Khan N, Meo P, Unemo M. In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea? J Antimicrob Chemother. 2019;74(6):1591\u20134. https:\/\/doi.org\/10.1093\/jac\/dkz060.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"1530_CR107","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1093\/jac\/dkaa322","volume":"75","author":"S Jacobsson","year":"2020","unstructured":"Jacobsson S, Mason C, Khan N, Meo P, Unemo M. High in vitro activity of DIS-73285, a novel antimicrobial with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2020;75(11):3244\u20137. https:\/\/doi.org\/10.1093\/jac\/dkaa322.","journal-title":"J Antimicrob Chemother"},{"key":"1530_CR108","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02380-17","author":"S Paukner","year":"2018","unstructured":"Paukner S, Gruss A, Jensen JS. In vitro activity of lefamulin against sexually transmitted bacterial pathogens. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.02380-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1530_CR109","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01497-17","author":"S Jacobsson","year":"2017","unstructured":"Jacobsson S, Paukner S, Golparian D, Jensen JS, Unemo M. In Vitro Activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.01497-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1530_CR110","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/phar.2166","volume":"38","author":"MP Veve","year":"2018","unstructured":"Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018;38(9):935\u201346. https:\/\/doi.org\/10.1002\/phar.2166.","journal-title":"Pharmacotherapy"},{"key":"1530_CR111","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00325-18","author":"MM Butler","year":"2018","unstructured":"Butler MM, Waidyarachchi SL, Connolly KL, Jerse AE, Chai W, Lee RE, et al. Aminomethyl spectinomycins as therapeutics for drug-resistant gonorrhea and chlamydia coinfections. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.00325-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1530_CR112","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00929-17","author":"VF Miari","year":"2017","unstructured":"Miari VF, Solanki P, Hleba Y, Stabler RA, Heap JT. In vitro susceptibility to closthioamide among clinical and reference strains of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.00929-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1530_CR113","first-page":"116","volume":"62","author":"T Muratani","year":"2009","unstructured":"Muratani T, Doi K, Kobayashi T, Nakamura T, Matsumoto T. Antimicrobial activity of tebipenem against various clinical isolates from various specimen, mainly urinary tract. Jpn J Antibiot. 2009;62(2):116\u201326.","journal-title":"Jpn J Antibiot"},{"issue":"Supplement_1","key":"1530_CR114","doi-asserted-by":"publisher","first-page":"S844","DOI":"10.1093\/ofid\/ofaa515.1900","volume":"7","author":"LA Muir","year":"2020","unstructured":"Muir LA, Walpole SM, Warfel PA, Kwak H, Phelan A-M, Moore GE, et al. LB-3. Oral tebipenem pivoxil hydrobromide is non-inferior TO IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP)\u2014results from the pivotal ADAPT-PO Study. Open Forum Infect Dis. 2020;7(Supplement_1):S844\u20135. https:\/\/doi.org\/10.1093\/ofid\/ofaa515.1900.","journal-title":"Open Forum Infect Dis"},{"issue":"Supplement_1","key":"1530_CR115","doi-asserted-by":"publisher","first-page":"S831-S","DOI":"10.1093\/ofid\/ofaa439.1873","volume":"7","author":"IA Critchley","year":"2020","unstructured":"Critchley IA, Cotroneo NS, Pucci MJ, Jain A, Mendes RE. 1695. Tebipenem: an oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US Medical Centers during 2019. Open Forum Infect Dis. 2020;7(Supplement_1):S831-S. https:\/\/doi.org\/10.1093\/ofid\/ofaa439.1873.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"1530_CR116","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.cell.2020.05.005","volume":"181","author":"JK Martin 2nd","year":"2020","unstructured":"Martin JK 2nd, Sheehan JP, Bratton BP, Moore GM, Mateus A, Li SH, et al. A dual-mechanism antibiotic kills gram-negative bacteria and avoids drug resistance. Cell. 2020;181(7):1518-32.e14. https:\/\/doi.org\/10.1016\/j.cell.2020.05.005.","journal-title":"Cell"},{"issue":"5","key":"1530_CR117","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/1120009x.2019.1615724","volume":"31","author":"S Jacobsson","year":"2019","unstructured":"Jacobsson S, Alirol E, Unemo M. In vitro activity of the ketolide cethromycin in multidrug-resistant clinical Neisseria gonorrhoeae isolates and international reference strains. J Chemother. 2019;31(5):246\u201351. https:\/\/doi.org\/10.1080\/1120009x.2019.1615724.","journal-title":"J Chemother"},{"key":"1530_CR118","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00467","author":"V Yarlagadda","year":"2020","unstructured":"Yarlagadda V, Medina R, Johnson TA, Koteva KP, Cox G, Thaker MN, et al. Resistance-guided discovery of elfamycin antibiotic producers with antigonococcal activity. ACS Infect Dis. 2020. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00467.","journal-title":"ACS Infect Dis."},{"issue":"41","key":"1530_CR119","doi-asserted-by":"publisher","first-page":"10364","DOI":"10.1002\/chem.201801602","volume":"24","author":"Y Sun","year":"2018","unstructured":"Sun Y, Zhang J, Zhang Y, Liu J, van der Veen S, Duttwyler S. The closo-dodecaborate dianion fused with oxazoles provides 3D diboraheterocycles with selective antimicrobial activity. Chemistry (Easton). 2018;24(41):10364\u201371. https:\/\/doi.org\/10.1002\/chem.201801602.","journal-title":"Chemistry (Easton)."},{"issue":"11","key":"1530_CR120","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1093\/jac\/dkz339","volume":"74","author":"CM John","year":"2019","unstructured":"John CM, Li M, Feng D, Jarvis GA. Cationic cell-penetrating peptide is bactericidal against Neisseria gonorrhoeae. J Antimicrob Chemother. 2019;74(11):3245\u201351. https:\/\/doi.org\/10.1093\/jac\/dkz339.","journal-title":"J Antimicrob Chemother"},{"issue":"25","key":"1530_CR121","doi-asserted-by":"publisher","first-page":"27994","DOI":"10.1021\/acsami.0c06163","volume":"12","author":"MI Luc\u00edo","year":"2020","unstructured":"Luc\u00edo MI, Kyriazi ME, Hamilton J, Batista D, Sheppard A, Sams-Dodd E, et al. Bactericidal effect of 5-mercapto-2-nitrobenzoic acid-coated silver nanoclusters against multidrug-resistant Neisseria gonorrhoeae. ACS Appl Mater Interfaces. 2020;12(25):27994\u20138003. https:\/\/doi.org\/10.1021\/acsami.0c06163.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"1530_CR122","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jiz018","volume":"220","author":"Y Wang","year":"2019","unstructured":"Wang Y, Ferrer-Espada R, Baglo Y, Goh XS, Held KD, Grad YH, et al. Photoinactivation of Neisseria gonorrhoeae: a paradigm-changing approach for combating antibiotic-resistant gonococcal infection. J Infect Dis. 2019;220(5):873\u201381. https:\/\/doi.org\/10.1093\/infdis\/jiz018.","journal-title":"J Infect Dis"},{"key":"1530_CR123","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fphar.2015.00180","volume":"6","author":"H Oliveira","year":"2015","unstructured":"Oliveira H, Sillankorva S, Merabishvili M, Kluskens LD, Azeredo J. Unexploited opportunities for phage therapy. Front Pharmacol. 2015;6:180. https:\/\/doi.org\/10.3389\/fphar.2015.00180.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1530_CR124","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","volume":"8","author":"DM Lin","year":"2017","unstructured":"Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162\u201373. https:\/\/doi.org\/10.4292\/wjgpt.v8.i3.162.","journal-title":"World J Gastrointest Pharmacol Ther."},{"issue":"1","key":"1530_CR125","doi-asserted-by":"publisher","first-page":"19386","DOI":"10.1038\/s41598-020-76184-1","volume":"10","author":"EPF Chow","year":"2020","unstructured":"Chow EPF, Maddaford K, Hocking JS, Bradshaw CS, Wigan R, Chen MY, et al. An open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2). Sci Rep. 2020;10(1):19386. https:\/\/doi.org\/10.1038\/s41598-020-76184-1.","journal-title":"Sci Rep"},{"key":"1530_CR126","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01339-19","author":"EA Semchenko","year":"2019","unstructured":"Semchenko EA, Everest-Dass AV, Jen FE, Mubaiwa TD, Day CJ, Seib KL. Glycointeractome of Neisseria gonorrhoeae: identification of host glycans targeted by the gonococcus to facilitate adherence to cervical and urethral epithelial cells. MBio. 2019. https:\/\/doi.org\/10.1128\/mBio.01339-19.","journal-title":"MBio"},{"issue":"10","key":"1530_CR127","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/infdis\/jiz628","volume":"221","author":"EA Semchenko","year":"2020","unstructured":"Semchenko EA, Mubaiwa TD, Day CJ, Seib KL. Role of the gonococcal neisserial heparin binding antigen in microcolony formation, and serum resistance and adherence to epithelial cells. J Infect Dis. 2020;221(10):1612\u201322. https:\/\/doi.org\/10.1093\/infdis\/jiz628.","journal-title":"J Infect Dis"},{"issue":"7","key":"1530_CR128","doi-asserted-by":"publisher","first-page":"e1007080","DOI":"10.1371\/journal.ppat.1007080","volume":"14","author":"SA Ragland","year":"2018","unstructured":"Ragland SA, Humbert MV, Christodoulides M, Criss AK. Neisseria gonorrhoeae employs two protein inhibitors to evade killing by human lysozyme. PLoS Pathog. 2018;14(7):e1007080. https:\/\/doi.org\/10.1371\/journal.ppat.1007080.","journal-title":"PLoS Pathog"},{"key":"1530_CR129","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00949-20","author":"MT Kammerman","year":"2020","unstructured":"Kammerman MT, Bera A, Wu R, Harrison SA, Maxwell CN, Lundquist K, et al. Molecular insight into TdfH-mediated zinc piracy from human calprotectin by Neisseria gonorrhoeae. MBio. 2020. https:\/\/doi.org\/10.1128\/mBio.00949-20.","journal-title":"MBio"},{"issue":"4","key":"1530_CR130","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1074\/jbc.RA117.000437","volume":"293","author":"AE Sikora","year":"2018","unstructured":"Sikora AE, Wierzbicki IH, Zielke RA, Ryner RF, Korotkov KV, Buchanan SK, et al. Structural and functional insights into the role of BamD and BamE within the \u03b2-barrel assembly machinery in Neisseria gonorrhoeae. J Biol Chem. 2018;293(4):1106\u201319. https:\/\/doi.org\/10.1074\/jbc.RA117.000437.","journal-title":"J Biol Chem"},{"issue":"36","key":"1530_CR131","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","volume":"33","author":"AP Craig","year":"2015","unstructured":"Craig AP, Gray RT, Edwards JL, Apicella MA, Jennings MP, Wilson DP, et al. The potential impact of vaccination on the prevalence of gonorrhea. Vaccine. 2015;33(36):4520\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.015.","journal-title":"Vaccine"},{"issue":"1","key":"1530_CR132","first-page":"29","volume":"65","author":"L Greenberg","year":"1974","unstructured":"Greenberg L, Diena BB, Ashton FA, Wallace R, Kenny CP, Znamirowski R, et al. Gonococcal vaccine studies in Inuvik. Can J Public Health. 1974;65(1):29\u201333.","journal-title":"Can J Public Health"},{"issue":"1","key":"1530_CR133","first-page":"34","volume":"14","author":"L Greenberg","year":"1975","unstructured":"Greenberg L. Field trials of a gonococcal vaccine. J Reprod Med. 1975;14(1):34\u20136.","journal-title":"J Reprod Med"},{"key":"1530_CR134","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/fmb-2017-0262","volume":"13","author":"MW Russell","year":"2018","unstructured":"Russell MW. Could vaccination against Neisseria gonorrhoeae be on the horizon? Future Microbiol. 2018;13:495\u20137. https:\/\/doi.org\/10.2217\/fmb-2017-0262.","journal-title":"Future Microbiol"},{"issue":"1","key":"1530_CR135","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0264-410x(85)90003-9","volume":"3","author":"EC Tramont","year":"1985","unstructured":"Tramont EC, Boslego JW. Pilus vaccines. Vaccine. 1985;3(1):3\u201310. https:\/\/doi.org\/10.1016\/0264-410x(85)90003-9.","journal-title":"Vaccine"},{"issue":"3","key":"1530_CR136","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0264-410x(91)90147-x","volume":"9","author":"JW Boslego","year":"1991","unstructured":"Boslego JW, Tramont EC, Chung RC, McChesney DG, Ciak J, Sadoff JC, et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine. 1991;9(3):154\u201362. https:\/\/doi.org\/10.1016\/0264-410x(91)90147-x.","journal-title":"Vaccine"},{"issue":"26","key":"1530_CR137","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","volume":"34","author":"SL Gottlieb","year":"2016","unstructured":"Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. Vaccine. 2016;34(26):2939\u201347. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.111.","journal-title":"Vaccine"},{"issue":"50","key":"1530_CR138","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1016\/j.vaccine.2018.02.081","volume":"37","author":"LR Vincent","year":"2019","unstructured":"Vincent LR, Jerse AE. Biological feasibility and importance of a gonorrhea vaccine for global public health. Vaccine. 2019;37(50):7419\u201326. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.081.","journal-title":"Vaccine"},{"issue":"1","key":"1530_CR139","doi-asserted-by":"publisher","first-page":"e87688","DOI":"10.1371\/journal.pone.0087688","volume":"9","author":"SM Zughaier","year":"2014","unstructured":"Zughaier SM, Kandler JL, Shafer WM. Neisseria gonorrhoeae modulates iron-limiting innate immune defenses in macrophages. PLoS ONE. 2014;9(1):e87688. https:\/\/doi.org\/10.1371\/journal.pone.0087688.","journal-title":"PLoS ONE"},{"issue":"3","key":"1530_CR140","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/mi.2009.139","volume":"3","author":"B Feinen","year":"2010","unstructured":"Feinen B, Jerse AE, Gaffen SL, Russell MW. Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal Immunol. 2010;3(3):312\u201321. https:\/\/doi.org\/10.1038\/mi.2009.139.","journal-title":"Mucosal Immunol"},{"issue":"3","key":"1530_CR141","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mi.2012.12","volume":"5","author":"Y Liu","year":"2012","unstructured":"Liu Y, Islam EA, Jarvis GA, Gray-Owen SD, Russell MW. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-\u03b2-dependent mechanisms. Mucosal Immunol. 2012;5(3):320\u201331. https:\/\/doi.org\/10.1038\/mi.2012.12.","journal-title":"Mucosal Immunol"},{"issue":"7","key":"1530_CR142","doi-asserted-by":"publisher","first-page":"e41260","DOI":"10.1371\/journal.pone.0041260","volume":"7","author":"W Zhu","year":"2012","unstructured":"Zhu W, Ventevogel MS, Knilans KJ, Anderson JE, Oldach LM, McKinnon KP, et al. Neisseria gonorrhoeae suppresses dendritic cell-induced, antigen-dependent CD4 T cell proliferation. PLoS ONE. 2012;7(7):e41260. https:\/\/doi.org\/10.1371\/journal.pone.0041260.","journal-title":"PLoS ONE"},{"issue":"10","key":"1530_CR143","doi-asserted-by":"publisher","first-page":"6460","DOI":"10.4049\/jimmunol.0802696","volume":"182","author":"JA Duncan","year":"2009","unstructured":"Duncan JA, Gao X, Huang MT, O\u2019Connor BP, Thomas CE, Willingham SB, et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol. 2009;182(10):6460\u20139. https:\/\/doi.org\/10.4049\/jimmunol.0802696.","journal-title":"J Immunol"},{"issue":"11","key":"1530_CR144","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.vaccine.2015.01.057","volume":"33","author":"R Pajon","year":"2015","unstructured":"Pajon R, Buckwalter CM, Johswich KO, Gray-Owen SD, Granoff DM. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice. Vaccine. 2015;33(11):1317\u201323. https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.057.","journal-title":"Vaccine"},{"issue":"12","key":"1530_CR145","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1128\/iai.00781-07","volume":"75","author":"ML Zarantonelli","year":"2007","unstructured":"Zarantonelli ML, Szatanik M, Giorgini D, Hong E, Huerre M, Guillou F, et al. Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect Immun. 2007;75(12):5609\u201314. https:\/\/doi.org\/10.1128\/iai.00781-07.","journal-title":"Infect Immun"},{"issue":"7","key":"1530_CR146","doi-asserted-by":"publisher","first-page":"e1005043","DOI":"10.1371\/journal.ppat.1005043","volume":"11","author":"D Ermert","year":"2015","unstructured":"Ermert D, Shaughnessy J, Joeris T, Kaplan J, Pang CJ, Kurt-Jones EA, et al. Virulence of group A streptococci is enhanced by human complement inhibitors. PLoS Pathog. 2015;11(7):e1005043. https:\/\/doi.org\/10.1371\/journal.ppat.1005043.","journal-title":"PLoS Pathog"},{"issue":"4","key":"1530_CR147","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/mi.2015.122","volume":"9","author":"EA Islam","year":"2016","unstructured":"Islam EA, Shaik-Dasthagirisaheb Y, Kaushic C, Wetzler LM, Gray-Owen SD. The reproductive cycle is a pathogenic determinant during gonococcal pelvic inflammatory disease in mice. Mucosal Immunol. 2016;9(4):1051\u201364. https:\/\/doi.org\/10.1038\/mi.2015.122.","journal-title":"Mucosal Immunol"},{"issue":"10102","key":"1530_CR148","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/s0140-6736(17)31449-6","volume":"390","author":"H Petousis-Harris","year":"2017","unstructured":"Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(17)31449-6.","journal-title":"Lancet"},{"key":"1530_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010005","author":"J Paynter","year":"2019","unstructured":"Paynter J, Goodyear-Smith F, Morgan J, Saxton P, Black S, Petousis-Harris H. Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study. Vaccines (Basel). 2019. https:\/\/doi.org\/10.3390\/vaccines7010005.","journal-title":"Vaccines (Basel)."},{"key":"1530_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010031","author":"C Kenyon","year":"2019","unstructured":"Kenyon C. Comment on \"Effectiveness of a Group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study, Vaccines, 2019, 1, 5; doi:10.3390\/vaccines7010005. Vaccines (Basel). 2019. https:\/\/doi.org\/10.3390\/vaccines7010031.","journal-title":"Vaccines (Basel)"},{"key":"1530_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010032","author":"J Paynter","year":"2019","unstructured":"Paynter J, Goodyear-Smith F, Morgan J, Saxton P, Black S, Petousis-Harris H. Reply to \u201cComment on Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study, Vaccines, 2019, 1, 5; doi:10.3390\/vaccines7010005.\u201d Vaccines (Basel). 2019. https:\/\/doi.org\/10.3390\/vaccines7010032.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"1530_CR152","doi-asserted-by":"publisher","first-page":"110","DOI":"10.7774\/cevr.2019.8.2.110","volume":"8","author":"RFO Azze","year":"2019","unstructured":"Azze RFO. A meningococcal B vaccine induces cross-protection against gonorrhea. Clin Exp Vaccine Res. 2019;8(2):110\u20135. https:\/\/doi.org\/10.7774\/cevr.2019.8.2.110.","journal-title":"Clin Exp Vaccine Res."},{"issue":"6","key":"1530_CR153","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3201\/eid2206.151093","volume":"22","author":"J Whelan","year":"2016","unstructured":"Whelan J, Kl\u00f8vstad H, Haugen IL, Holle MR-DRB, Storsaeter J. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection Norway. Emerg Infect Dis. 2016;22(6):1137\u20139. https:\/\/doi.org\/10.3201\/eid2206.151093.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"1530_CR154","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","volume":"69","author":"EA Semchenko","year":"2019","unstructured":"Semchenko EA, Tan A, Borrow R, Seib KL. The serogroup B meningococcal vaccine bexsero elicits antibodies to Neisseria gonorrhoeae. Clin Infect Dis. 2019;69(7):1101\u201311. https:\/\/doi.org\/10.1093\/cid\/ciy1061.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1530_CR155","doi-asserted-by":"publisher","first-page":"e1008602","DOI":"10.1371\/journal.ppat.1008602","volume":"16","author":"I Leduc","year":"2020","unstructured":"Leduc I, Connolly KL, Begum A, Underwood K, Darnell S, Shafer WM, et al. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog. 2020;16(12):e1008602. https:\/\/doi.org\/10.1371\/journal.ppat.1008602.","journal-title":"PLoS Pathog"},{"key":"1530_CR156","unstructured":"Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04350138. Accessed 15 Jan 2021."},{"key":"1530_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6030060","author":"RP Gala","year":"2018","unstructured":"Gala RP, Zaman RU, D\u2019Souza MJ, Zughaier SM. Novel whole-cell inactivated Neisseria gonorrhoeae microparticles as vaccine formulation in microneedle-based transdermal immunization. Vaccines (Basel). 2018. https:\/\/doi.org\/10.3390\/vaccines6030060.","journal-title":"Vaccines (Basel)."},{"issue":"30","key":"1530_CR158","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1016\/j.vaccine.2018.06.006","volume":"36","author":"H Jiao","year":"2018","unstructured":"Jiao H, Yang H, Zhao D, Chen J, Zhang Q, Liang J, et al. Design and immune characterization of a novel Neisseria gonorrhoeae DNA vaccine using bacterial ghosts as vector and adjuvant. Vaccine. 2018;36(30):4532\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.006.","journal-title":"Vaccine"},{"issue":"8","key":"1530_CR159","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/2211-5463.12267","volume":"7","author":"L Wang","year":"2017","unstructured":"Wang L, Xing D, Le Van A, Jerse AE, Wang S. Structure-based design of ferritin nanoparticle immunogens displaying antigenic loops of Neisseria gonorrhoeae. FEBS Open Bio. 2017;7(8):1196\u2013207. https:\/\/doi.org\/10.1002\/2211-5463.12267.","journal-title":"FEBS Open Bio"},{"issue":"7456","key":"1530_CR160","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499(7456):102\u20136. https:\/\/doi.org\/10.1038\/nature12202.","journal-title":"Nature"},{"issue":"5","key":"1530_CR161","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U, et al. Rational design of an epstein-barr virus vaccine targeting the receptor-binding site. Cell. 2015;162(5):1090\u2013100. https:\/\/doi.org\/10.1016\/j.cell.2015.07.043.","journal-title":"Cell"},{"issue":"7","key":"1530_CR162","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1074\/mcp.M116.058800","volume":"15","author":"RA Zielke","year":"2016","unstructured":"Zielke RA, Wierzbicki IH, Baarda BI, Gafken PR, Soge OO, Holmes KK, et al. Proteomics-driven antigen discovery for development of vaccines against gonorrhea. Mol Cell Proteomics. 2016;15(7):2338\u201355. https:\/\/doi.org\/10.1074\/mcp.M116.058800.","journal-title":"Mol Cell Proteomics"},{"key":"1530_CR163","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fimmu.2019.00321","volume":"10","author":"S Gulati","year":"2019","unstructured":"Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting lipooligosaccharide (LOS) for a gonococcal vaccine. Front Immunol. 2019;10:321. https:\/\/doi.org\/10.3389\/fimmu.2019.00321.","journal-title":"Front Immunol"},{"key":"1530_CR164","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02552-19","author":"S Gulati","year":"2019","unstructured":"Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak NA, et al. Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine. MBio. 2019. https:\/\/doi.org\/10.1128\/mBio.02552-19.","journal-title":"MBio"},{"key":"1530_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8020065","author":"AS Brott","year":"2019","unstructured":"Brott AS, Jones CS, Clarke AJ. Development of a high throughput screen for the identification of inhibitors of peptidoglycan O-acetyltransferases, new potential antibacterial targets. Antibiotics (Basel). 2019. https:\/\/doi.org\/10.3390\/antibiotics8020065.","journal-title":"Antibiotics (Basel)."},{"key":"1530_CR166","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131886","author":"S Bettoni","year":"2019","unstructured":"Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, et al. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.131886.","journal-title":"JCI Insight."},{"issue":"10","key":"1530_CR167","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/infdis\/jiaa438","volume":"222","author":"S Gulati","year":"2020","unstructured":"Gulati S, Schoenhofen IC, Lindhout-Djukic T, Lewis LA, Moustafa IY, Saha S, et al. Efficacy of antigonococcal CMP-nonulosonate therapeutics require cathelicidins. J Infect Dis. 2020;222(10):1641\u201350. https:\/\/doi.org\/10.1093\/infdis\/jiaa438.","journal-title":"J Infect Dis"},{"issue":"9","key":"1530_CR168","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.4049\/jimmunol.1701666","volume":"201","author":"J Shaughnessy","year":"2018","unstructured":"Shaughnessy J, Lewis LA, Zheng B, Carr C, Bass I, Gulati S, et al. Human factor H domains 6 and 7 fused to IgG1 Fc are immunotherapeutic against Neisseria gonorrhoeae. J Immunol. 2018;201(9):2700\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1701666.","journal-title":"J Immunol"},{"issue":"3","key":"1530_CR169","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/pro.3824","volume":"29","author":"KF Barrett","year":"2020","unstructured":"Barrett KF, Dranow DM, Phan IQ, Michaels SA, Shaheen S, Navaluna ED, et al. Structures of glyceraldehyde 3-phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatis. Protein Sci. 2020;29(3):768\u201378. https:\/\/doi.org\/10.1002\/pro.3824.","journal-title":"Protein Sci"},{"issue":"8","key":"1530_CR170","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1093\/jac\/dky151","volume":"73","author":"CM John","year":"2018","unstructured":"John CM, Feng D, Jarvis GA. Treatment of human challenge and MDR strains of Neisseria gonorrhoeae with LpxC inhibitors. J Antimicrob Chemother. 2018;73(8):2064\u201371. https:\/\/doi.org\/10.1093\/jac\/dky151.","journal-title":"J Antimicrob Chemother"},{"key":"1530_CR171","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00090-18","author":"Z Wang","year":"2018","unstructured":"Wang Z, Wang X, Lu P, Ni C, Li Y, van der Veen S. Identification and characterization of the Neisseria gonorrhoeae MscS-like mechanosensitive channel. Infect Immun. 2018. https:\/\/doi.org\/10.1128\/iai.00090-18.","journal-title":"Infect Immun"},{"key":"1530_CR172","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01576-19","author":"S Chen","year":"2019","unstructured":"Chen S, Connolly KL, Rouquette-Loughlin C, D\u2019Andrea A, Jerse AE, Shafer WM. Could dampening expression of the Neisseria gonorrhoeae mtrCDE-encoded efflux pump be a strategy to preserve currently or resurrect formerly used antibiotics to treat gonorrhea? MBio. 2019. https:\/\/doi.org\/10.1128\/mBio.01576-19.","journal-title":"MBio"},{"key":"1530_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7040153","author":"T Zhu","year":"2019","unstructured":"Zhu T, McClure R, Harrison OB, Genco C, Massari P. Integrated bioinformatic analyses and immune characterization of new Neisseria gonorrhoeae vaccine antigens expressed during natural mucosal infection. Vaccines (Basel). 2019. https:\/\/doi.org\/10.3390\/vaccines7040153.","journal-title":"Vaccines (Basel)."},{"key":"1530_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.10.077","author":"AE Sikora","year":"2020","unstructured":"Sikora AE, Gomez C, Le Van A, Baarda BI, Darnell S, Martinez FG, et al. A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection. Vaccine. 2020. https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.077.","journal-title":"Vaccine"},{"issue":"3","key":"1530_CR175","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jinf.2018.06.001","volume":"77","author":"S Wang","year":"2018","unstructured":"Wang S, Xue J, Lu P, Ni C, Cheng H, Han R, et al. Gonococcal MtrE and its surface-expressed loop 2 are immunogenic and elicit bactericidal antibodies. J Infect. 2018;77(3):191\u2013204. https:\/\/doi.org\/10.1016\/j.jinf.2018.06.001.","journal-title":"J Infect"},{"key":"1530_CR176","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00331-18","author":"HL Almonacid-Mendoza","year":"2018","unstructured":"Almonacid-Mendoza HL, Humbert MV, Dijokaite A, Cleary DW, Soo Y, Hung MC, et al. Structure of the recombinant neisseria gonorrhoeae adhesin complex protein (rNg-ACP) and generation of murine antibodies with bactericidal activity against gonococci. mSphere. 2018. https:\/\/doi.org\/10.1128\/mSphere.00331-18.","journal-title":"mSphere."},{"issue":"27","key":"1530_CR177","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1016\/j.vaccine.2018.05.069","volume":"36","author":"MV Humbert","year":"2018","unstructured":"Humbert MV, Christodoulides M. Immunization with recombinant truncated Neisseria meningitidis-macrophage infectivity potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae. Vaccine. 2018;36(27):3926\u201336. https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.069.","journal-title":"Vaccine"},{"issue":"7","key":"1530_CR178","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1128\/iai.73.7.3945-3953.2005","volume":"73","author":"GA Price","year":"2005","unstructured":"Price GA, Russell MW, Cornelissen CN. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice. Infect Immun. 2005;73(7):3945\u201353. https:\/\/doi.org\/10.1128\/iai.73.7.3945-3953.2005.","journal-title":"Infect Immun"},{"issue":"11","key":"1530_CR179","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1128\/iai.00762-15","volume":"83","author":"DR Cash","year":"2015","unstructured":"Cash DR, Noinaj N, Buchanan SK, Cornelissen CN. Beyond the crystal structure: insight into the function and vaccine potential of TbpA expressed by Neisseria gonorrhoeae. Infect Immun. 2015;83(11):4438\u201349. https:\/\/doi.org\/10.1128\/iai.00762-15.","journal-title":"Infect Immun"},{"issue":"2","key":"1530_CR180","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bbrc.2012.12.132","volume":"431","author":"LK Shewell","year":"2013","unstructured":"Shewell LK, Ku SC, Schulz BL, Jen FE, Mubaiwa TD, Ketterer MR, et al. Recombinant truncated AniA of pathogenic Neisseria elicits a non-native immune response and functional blocking antibodies. Biochem Biophys Res Commun. 2013;431(2):215\u201320. https:\/\/doi.org\/10.1016\/j.bbrc.2012.12.132.","journal-title":"Biochem Biophys Res Commun"},{"key":"1530_CR181","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fmicb.2011.00124","volume":"2","author":"W Zhu","year":"2011","unstructured":"Zhu W, Chen CJ, Thomas CE, Anderson JE, Jerse AE, Sparling PF. Vaccines for gonorrhea: can we rise to the challenge? Front Microbiol. 2011;2:124. https:\/\/doi.org\/10.3389\/fmicb.2011.00124.","journal-title":"Front Microbiol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01530-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01530-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01530-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T12:24:50Z","timestamp":1626351890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01530-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":181,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01530-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"28 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the National Institutes of Health [R21 AI157817 to JDK and T32MH080634 to PCA].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors (E.Y.L., P.C.A., J.D.K.) significantly contributed to the research and writing of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}